| Code | CSB-RA001346MB1HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is developed as a research-grade biosimilar to the reference antibody ALD-1910, targeting ADCYAP1 (Adenylate Cyclase Activating Polypeptide 1), also known as pituitary adenylate cyclase-activating polypeptide (PACAP). ADCYAP1 is a neuropeptide belonging to the vasoactive intestinal peptide (VIP)/secretin/glucagon superfamily that plays critical roles in neurotransmission, neuroprotection, and neuroendocrine regulation. This peptide functions through activation of G protein-coupled receptors and modulates diverse physiological processes including stress responses, circadian rhythms, and neuronal survival. ADCYAP1 has been implicated in various neurological and psychiatric conditions, including migraine, post-traumatic stress disorder, neurodegenerative diseases, and metabolic disorders.
As a biosimilar to ALD-1910, this antibody provides researchers with a validated tool for investigating ADCYAP1 expression, localization, and function in neural and endocrine tissues. It supports studies examining PACAP signaling pathways, stress-related disorders, and potential therapeutic interventions targeting this neuropeptide system. This reagent is suitable for advancing understanding of neuroendocrine mechanisms and disease pathophysiology.
There are currently no reviews for this product.